The 2016 version of the WHO lymphoma classification suggests that C-MYC genetic alteration is one of the important diagnostic indicators of DLBCL, and defines DHL and THL as high-grade B-cell lymphoma (Arber et al., 2016). This evidence concerns the gene MYC and B-cell non-Hodgkin lymphoma.